Articles
Will the Biogen Drug Approval Be a Boon for Biotech?
Final week, the FDA accepted Biogen’s Alzheimer’s drug candidate, aducanumab (marketed as Aduhelm). This approval seems to be more likely to be a watershed second
March 17, 2023
No Comments
